Vaccinations in multiple sclerosis patients receiving disease-modifying drugs

Area of Science:

• Neurology
• Immunology
• Vaccinology

Background:

• Multiple sclerosis (MS) management involves disease-modifying drugs (DMDs) that can impact immune responses.
• The introduction of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates a review of immunization strategies in MS patients.

Purpose of the Study:

• To review new evidence supporting global immunization strategies for MS patients on DMDs.
• To assess the safety and efficacy of vaccines, including SARS-CoV-2 vaccines, in the context of MS treatment.

Main Methods:

• Review of recent scientific literature and consensus statements on MS and vaccination.
• Analysis of data regarding vaccine immunogenicity and safety in patients receiving various DMDs.
• Consideration of the impact of specific DMDs, such as B-cell depleting therapies, on vaccine response.

Main Results:

• New evidence refutes a causal link between MS and vaccination.
• Early vaccination is recommended, with timing adjusted to optimize response and safety.
• Patients on B-cell depleting therapies (e.g., Ocrelizumab) may exhibit diminished immunogenicity to vaccines, including SARS-CoV-2 vaccines.

Conclusions:

• Early immunization assessment and administration in MS patients are crucial for optimizing vaccine responses and avoiding treatment interference.
• Vaccinations are generally safe and effective, but specific timing relative to immunotherapy is important.
• Further research into SARS-CoV-2 vaccine response dynamics in MS patients on specific therapies is needed to refine vaccination strategies.